TSBX Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.29 and $2.26. With a market capitalization of about $8.21 million, Turnstone Biologics Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.37). Key stats such as the average daily volume over the past year has been around 404.93 thousand shares, in line with its 52-week average. Headquartered in LA Jolla, CA, Turnstone Biologics Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sammy J. Farah, the company employs approximately 14 people and listed since July 21, 2023. Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors.

Short-term trend indicators are mixed aligned (SMA20 -0.38%, SMA50 -0.19%, SMA200 -13.72%). The stock’s 14-day RSI is 49.25 (neutral), while the ATR of 0.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.33% below its high and over 22.41% above its low.

Turnstone Biologics Corp. trades at a P/E ratio of -0.27, slightly below the S&P 500 average, with a price-to-sales ratio of 4.07 and a price-to-book ratio of 0.56 suggesting the stock is closer to book value. The P/FCF stands at -0.29, also above market averages.

Turnstone Biologics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.20. This means the shares are trading below this model’s fair value.